Humira (adalimumab) is a prescription drug that’s used to treat certain types of arthritis and other inflammation-related diseases. It comes as a liquid solution for injection under your skin.

The global intradermal injection market size is expected to surpass an impressive valuation of USD 3,878 Million in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 10.8% from ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

Weight loss pills and injections are two forms of medication used to help people lose weight. There are a number of medications approved for weight loss and they can work in a variety of ways ...

More patients transitioned to Sandoz's biosimilar version of Humira in just three weeks than in the previous 15 months combined. Despite the growing competition, AbbVie has managed to retain a ...

This advantage is unlikely to be replicated by fixed-dose injections Humira, Cosentyx, and bimekizumab. Vilobelimab is an IV biologic. The companies mentioned in this article did not respond to a ...

Simlandi is indicated for many chronic autoimmune conditions. Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis ...

which carries a 5% discount to Humira, and the other an unbranded copycat simply called adalimumab-adbm injection that’s sold at an 81% markdown. As of last October, a month’s supply of ...

Simlandi is the first interchangeable, citrate-free Humira biosimilar available in ... for interchangeable exclusivity as a 40 mg/0.4 mL injection, according to the release. Its approval comes ...

In November 2023, the FDA accepted a Supplemental Biologics License Application (sBLA) for interchangeability designation for a new adalimumab (Humira) biosimilar, adalimumab-bwwd (Hadlima; Samsung ...

Elevance Health's CarelonRx is the latest pharmacy benefit manager to put biosimilars for popular drug Humira on its formulary, the company said this week. Beginning Dec. 1, adalimumab-adbm will ...

After debuting its branded Humira biosim Cyltezo in July, Boehringer has launched an unbranded copycat of the inflammatory disease drug, simply called adalimumab-adbm injection, which will be sold ...